The company is managed by 19 executives with total tenure of roughly 70 years, averaging almost 3.0 years of service per executive having 38.95 employees per reported executive. However, they must report all trades to the SEC via a Form … Ultragenyx Pharmaceutical (NASDAQ:RARE) has promoted Erik Harris to Executive Vice President and Chief Commercial Officer (CCO), effective June 11. Erik Harris Executive Vice President and Chief Commercial Officer at Ultragenyx Pharmaceutical Inc. San Francisco Bay Area.

“Ultragenyx has made tremendous progress in establishing a global commercial organization that has rapidly provided access to two important therapies, and I am excited to build on the launch momentum as we bring these medicines to more patients around the world,” said Erik Harris. Rare disease company Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) promoted Erik Harris to EVP and chief commercial officer from SVP, head of North American commercial operations.. Bispecific antibody company F-star Biotechnology Ltd. (Cambridge, U.K.) said CFO Tolga See others named Erik Harris Add new skills with these courses. Erik Harris. Dear Erik, This addendum will supersede the equity grant section of the previously signed offer of employment dated May 16, 2017. He joined Ultragenyx in 2017 as Senior Vice President, Head of North American Commercial Operations, and was promoted to Chief Commercial Officer in June 2019. It is illegal for insiders to make trades in their companies based on specific, non-public information. See others named Erik Harris Add new skills with these courses. This does not mean it is illegal for them to make any trades in their own companies. Rare disease company Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) promoted Erik Harris to EVP and chief commercial officer from SVP, head of North American commercial operations. Management tracks: Ultragenyx promotes Erik Harris; plus F-star, Arbutus, Maze and more Rare disease company Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) promoted Erik Harris to EVP and chief commercial officer from SVP, head of North American commercial operations. Erik Harris. Erik Harris is Exec VP/Chief Commercial Officer at Ultragenyx Pharmaceutical Inc. See Erik Harris's compensation, career history, education, & memberships. Erik C. Harris EVP & Chief Commercial Officer: 209: Derivative/Non-derivative trans. His experience also includes posts at Crescendo Bioscience and Intermune. Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced it has promoted Erik Harris to Executive Vice President and Chief Commercial Officer, effective June 11, 2019. Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced it … Erik Harris. Mr. Harris 93 others named Erik Harris are on LinkedIn. Last year, Ultragenyx won FDA approval for burosumab […] Greater Seattle Area. The company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for … NOVATO, Calif., June 17, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced it has promoted Erik Harris to Executive Vice President and Chief Commercial Officer, effective June 11, 2019. Erik Harris serves as Executive Vice President and Chief Commercial Officer. Erik Harris. Prior to Ultragenyx, Mr. Harris spent six years at Crescendo Bioscience, a subsidiary of Myriad Genetics, Inc. At Crescendo he held … New Hire Equity Awards Mr. Harris The Company has increased your original option grant of 15,000 to 30,000 effective with the commencement of your employment with Ultragenyx. Erik Harris is listed as an insider in the following companies: RARE / Ultragenyx Pharmaceutical Inc. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support

Ultragenyx Pharmaceutical employes about 740 people. Erik Harris. RARE - key executives, insider trading, ownership, revenue and average growth rates. Erik Harris Executive Vice President and Chief Commercial Officer at Ultragenyx Pharmaceutical Inc. San Francisco Bay Area. Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Erik Harris Chief Commercial Officer and Executive Vice President.